Conference presentation
English

Linking antibody against apolipoprotein A-1 to metabolic dysfunction-associatedsteatohepatitis in mice

Presented atESC (Europan Society of Cardiology) Congress 2024, London (UK), 30 August–02 September 2024
Presentation date2024
Abstract

Background : Metabolic dysfunction-associated fatty liver disease (MASLD) is a common liver condition associated with increased cardiovascular disease (CVD) risk. Cytokeratin 18 (CK-18) is indicative of liver injury and used as a surrogate biomarker covering MASLD to cirrhosis phenotypes. Autoantibodies against apolipoprotein A-1 (AAA-1) are known CVD risk factors inducing MASLD in vitro, but their role in modulating steatohepatitis and fibrosis in vivo is still elusive. We investigated AAA-1's contribution to systemic low-grade inflammation, liver steatosis, and fibrosis using a MASLD mouse model and a validated passive immunization protocol (PIP).

Methods : 10 weeks-old male C57BL/6J mice were fed a choline-deficient, L-amino acid-defined, high-fat diet (CDAHFD) and immunized with AAA-1 (200ug) or control antibodies for ten days. At sacrifice, plasma samples were collected, and CK-18 levels, and proinflammatory cytokines were measured using the Mesoscale Discovery platform. Hematoxylin and Eosin and Sirius Red Fast Green staining were used to reveal liver steatosis and fibrosis, respectively. RNA were extracted from mouse liver samples and mRNA were then analyzed using a commercial fibrosis-specific genes panel (nCounter Human Fibrosis V2 Panel) and the nCounter Analysis System.

Results : Compared to control IgG recipients, CDAHFD mice injected with AAA-1 exhibited significantly elevated plasma levels of CK-18 (5.3 vs 2.1, p=0.031), IL-6 (13 vs 6.9, p=0.035), IL-10 (27.3 vs 9.8, p=0.007) and TNF-α (32.1 vs 24.2, p=0.032), and liver steatosis (93.4% vs 73.8%, p=0.007). Nanostring technology experiments revealed upregulation of several pro-fibrotic m-RNAs in liver tissue from AAA-1 immunized mice compared to the IgG immunized control group. These included Serum Amyloid A (Fold Change (FC) AAA-1 vs IgG : 2.5, p=0.02) , G-protein coupled receptors 65 (FC: 2.7, p=0.01), Periostin (FC: 2.6, p=0.001), Phospholipid transfer protein (FC: 2.2, p=0.0004), Vascular Cell Adhesion Molecule 1 (FC: 2.5, p=0.02) and Angiopoietin-like 4 (FC: 2.8, p=0.01). Histologically, the amount of liver fibrosis remained unaffected, probably due to the short time of the study.

Conclusions : Short AAA-1 PIP induced enhanced liver steatosis and inflammation accompanied by an elevation of the expression of several pro-fibrotic genes in CDAHFD mice, suggesting that AAA-1 may contribute to the transition from MASLD to MASH. Knowing whether increased exposure time to AAA-1 could lead to end stage disease (including cirrhosis and HCC), and if this could apply to humans as well warrant further investigations.

Keywords
  • Cytokine
  • Phenotype
  • Tumor necrosis factors
  • Cardiovascular diseases
  • Liver injuries
  • Heart disease risk factors
  • Inflammation
  • Liver cirrhosis
  • Fatty liver
  • Fibrosis
  • Hepatic fibrosis
  • Serum amyloid a protein
  • Autoantibodies
  • Biological markers
  • Choline
  • Eosine yellowish-(ys)
  • Genes
  • Hematoxylin
  • Immunization
  • Passive immunization procedure
  • Interleukin-10
  • Keratins
  • Mice, inbred c57bl
  • Plasma
  • Rna, messenger
  • Up-regulation (physiology)
  • Vascular cell adhesion molecule-1
  • Immunoglobulin g
  • Antibodies
  • Apolipoprotein a-i
  • Interleukin-6
  • Liver
  • Mice
  • Steatohepatitis, non-alcoholic
  • G-protein-coupled receptors
  • Rna
  • Terminal illness
  • Angiopoietins
  • Sirius red
  • Phospholipid exchange proteins
  • Diet, high-fat
  • Periostin
  • Metabolic dysfunction-associated steatohepatitis
  • Metabolic dysfunction-associated steatotic liver disease
NotePublished in : European heart journal, 2024, 45(Suppl.1):ehae666.3857
Citation (ISO format)
PAGANO, Sabrina et al. Linking antibody against apolipoprotein A-1 to metabolic dysfunction-associatedsteatohepatitis in mice. In: ESC (Europan Society of Cardiology) Congress 2024. London (UK). 2024. doi: 10.1093/eurheartj/ehae666.3857
Secondary files (1)
Summary
Identifiers
8views
0downloads

Technical informations

Creation07/11/2025 15:51:44
First validation17/12/2025 09:10:29
Update17/12/2025 09:10:29
Status update17/12/2025 09:10:29
Last indexation17/12/2025 09:10:30
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack